We’re building something that wasn’t possible a decade ago.

Nucleus just closed our Series A, backed by 776 and Founders Fund, to accelerate whole genome sequencing at scale. Why now? Because it used to cost $100M to analyze a full human genome — now it’s a few hundred dollars. That shift is opening the door to personalized medicine that actually delivers: from family planning to drug dosage, our genetics hold the answers.

This isn’t the collapse of an industry. It’s the transformation of it.

Nucleus is now the only player with a physician-ordered, clinical-grade genomics platform that can return truly comprehensive health insights — securely, and at population scale.

We’re just getting started.

It used to cost $100 million to sequence a whole genome. Today, it's a few hundred dollars.

That shift didn’t just make testing cheaper—it made precision medicine possible. At Nucleus, we’re building on that shift by pairing whole genome sequencing with AI to help people plan families, understand their health risks, and personalize their treatment options.

And unlike legacy tools that offered ancestry reports with limited insights, what we’re building is actionable. It’s ordered by physicians, secured under medical-grade standards, and built to serve people on an individual level.

This is not just cheaper testing. This is a better healthcare infrastructure—one that puts the right information in the right person’s hands, at the right time.

Grateful to work alongside investors like Alexis Ohanian and 776 who understand that the genomic revolution isn’t in the future. It’s happening now.

AI won't just write your emails or drive your car. In healthcare, it's about to do something far more personal—and powerful.

When Alexis Ohanian and I spoke about Nucleus, we weren’t talking about incremental progress. We were talking about using whole genome sequencing—combined with powerful AI models—to unlock preventive, personalized medicine at scale.

Decoding a single genome used to cost $100 million. Now it’s a few hundred dollars. That shift doesn’t just change the economics—it changes who gets access and what’s possible.

Your DNA is a massive, complex dataset. Understanding it takes more than any single doctor could ever absorb. But AI can. And when we train on whole genomes—not tiny fragments—we're training on the real blueprint of human biology.

Precision drug matching. Proactive disease prevention. Family planning decisions based on data, not guesswork.

We’re just scratching the surface of what’s possible when medicine becomes data-driven on a genomic level. At Nucleus, we’re not just watching this shift happen—we're architecting it.

The cost to sequence a whole human genome used to be $100M. Now it’s a few hundred dollars. That’s not an incremental shift. That’s aviation-to-spaceflight territory. Nucleus just raised our Series A to make personalized gene-level healthcare a medical baseline, not a luxury.

It used to cost $100M to read your entire genome. Now it’s a few hundred dollars. That shift didn’t just kill old models like 23andMe—it made real personalized medicine finally possible. We built Nucleus to unlock that future.

Start with Alexis revealing how he's invested over $10 million in Nucleus. Cut quickly to Kian explaining why 23andMe failed, and how Nucleus is making full genome sequencing possible and useful. Land on the comparison between outdated DNA tests and what it means to actually understand your health at the level of your DNA. It’s the moment where the old promise of genomics finally gets replaced by something real.

Start with the shocking drop in cost: it used to be $100 million to decode your full DNA. Now it’s just a few hundred dollars. Without saying quotes directly, the video follows Kian explaining how this price revolution unlocks real personalized health care for the first time. He contrasts this with 23andMe’s limited testing and why most people didn’t get value from it. Then he hooks the viewer with what Nucleus can do instead: insights into your future kids, your medications, your unique risks—powered by AI. The clip ends with the powerful moment that positions Nucleus not as a Silicon Valley play, but as your actual, certified medical provider.

Start with Alexis saying the future is here and genomics is finally real. Then cut to Kian explaining why 23andMe didn’t work and what changed. He compares it to Netflix replacing Blockbuster. Today, AI can process your entire genome and actually give you answers. What drugs you should take. What conditions to look out for. Even how to plan a healthier family. End on Kian’s point: this isn’t science fiction anymore, it’s just data we finally know how to read.

Think about this: the cost of sequencing your entire genome used to be $100 million. Now it's a few hundred dollars. That shift isn't just about better tech — it's a window into radically personalized healthcare. It means knowing what treatments work for you, how to plan your family, even what medications your body will respond to. Most companies were stuck reading fragments. We’re reading the whole thing. That’s why this moment matters. That’s why we raised. Because the future is full-sequence, AI-powered, and built on trust.

It used to cost $100 million to look at your DNA. That’s why older genetic tests barely scratched the surface. Today, AI and computation have made full genome sequencing not only possible but affordable. And when you have access to your complete DNA, you unlock real, personal insights about your health, your future children, and what treatments will actually work for you. This isn’t about curiosity, it’s about control. Medical-grade data. Privacy as strict as your doctor’s office. Nucleus isn’t building a new test. We’re building the future of care.

What happens when AI meets your full genome? We're not talking fragments or ancestry reports—we're talking about understanding the entire 3 billion base pairs that make you, you. Kian lays out why this scale of genetic data, combined with today’s most powerful models, flips the healthcare script. This isn’t a futuristic bet. This is the shift. Personalized medicine is no longer hypothetical—it’s becoming the default.

23andMe collapsed. That’s not the end of consumer genomics. It’s the beginning of a massive shift. The $100M genome is now under $1,000. Nucleus isn’t just catching that wave — we’re building it. Full genomes, AI analysis, actual insights about your health. This isn’t ancestry trivia. It’s real medicine.

It used to cost $100 million to sequence your entire genome. Now it's a few hundred dollars. That shift doesn't just lower the price—it changes the game. Nucleus is using AI to turn your whole genome into actual medical insight. Drug dosages tailored to you. Family planning decisions built on your DNA. Real health outcomes, not genetic astrology. And your data? It's locked down like your hospital records. This isn’t the collapse of the genomics industry. This is the next phase. Personalized, secure, AI-driven medicine—finally available for everyone.

Most people think DNA tests only tell you ancestry or disease risk. That’s outdated. In this clip, Kian breaks down what’s actually possible when you combine whole genome sequencing with AI. Not just predictions, but decisions: what drugs you should avoid, how you should plan for kids, and how your health care changes when your doctor has access to *everything* in your code. This isn’t sci-fi. It’s regulated. It’s already live. And it’s about to change medicine forever.

The cost of sequencing a full human genome has dropped from nearly $100 million to just a few hundred dollars. This isn’t a minor price shift—it’s a complete reinvention of what’s possible in genomics. For decades, consumers expected little value from genetic tests because companies like 23andMe were limited to analyzing small portions of DNA. That limited analysis meant no insights into individual health, no guidance on family planning, no personalized medication dosages. At Nucleus Genomics, our view is very different. With AI, we're able to analyze entire genomes quickly and affordably, delivering real-world, medically relevant insight starting from a single swab.

Artificial intelligence isn’t just improving accuracy—it’s making population-scale personalized care viable. As a CLIA-certified and CAP-accredited medical provider, Nucleus isn’t a novelty or a toy. Our tests are physician-ordered, and the data is handled as securely as it would be in a hospital. Patients get full control over how, when, and where their data is used.

Too many people still fear sharing their genetic information. It’s time to set the record straight. Health insurers are legally barred from using your genetic information under the Genetic Information Nondiscrimination Act (GINA). That means safe access to a powerful tool that can help you understand disease risk, optimize treatment, and even ensure healthier children.

This is not the death of consumer genomics. It’s its transformation. And we’re leading it.